Answers are grounded in this paper and cite their sources.
The aim of this study is to evaluate the safety and gastrointestinal tolerance of Groviva® Advance in pediatric patients hospitalized to Pediatric Intensive Care Units (PICUs) and requiring an isocaloric formula for enteral tube feeding. This was a prospective five-day single centre, open label clinical study. The safety and tolerance of Groviva® Advance (45 gram in 170 millilitres of water) was evaluated every day from Day 1 to the end of hospitalization or Day 5, whichever was earlier. The reconstituted amount was 210 millilitres (equivalent to 200 kcal [1 kcal in 1 ml]) and dosed three hourly (or at the discretion of the pediatrician). The majority of participants received the Groviva® Advance tube feed three hourly on all five days of the study. The average range of total feeds varied from 295.16 ± 275.19 to 1074.737 ± 347.94 feeds per day. The most common side effects were loose stools or vomiting; if present, majority of participants had only one episode per day. There was minimal or no total daily aspiration or GRV (>500 ml/day). There was no statistically significant change in weight (P=0.7163) and abdominal girth (0.6381) of study participants. There were no issues encountered during the preparation and administration of Groviva® Advance. Groviva® Advance was found to be safe and well tolerated by critically ill children admitted to PICUs.
No takes yet. Share an insight, caveat, or question.
Dekate et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: